Immunoassays News and Research

RSS

Lateral flow assays detect a compound of interest in a compact, paper-based system. Tests such as pregnancy tests are based on lateral flow assays, with many more available for various compounds or even pathogens.

Effect of SARS-CoV-2 variant emergence on efficacy of neutralizing antibodies and vaccines

A review article focuses on the efficacy of neutralizing antibodies and vaccines against the SARS-CoV-2 variants.

9 Dec 2021

Equipment-free handheld microfluidic injection provides visible readout of SARS-CoV-2 detection

In this paper, a group of researchers from Harvard Medical School, McGill University, and Tianjin University describes an on-chip diagnostic technology for the direct detection of SARS-CoV-2 N protein in nasal samples that combines the advantages of hydrodynamic microfluidic filtration and sandwich immunoassay.

5 Dec 2021

Automate your sample pooling with INTEGRA’s efficient pipetting solutions

INTEGRA’s automated pipetting solutions are helping scientists meet the challenge of efficiently pooling potentially infectious samples prior to testing.

From INTEGRA Biosciences 3 Dec 2021

Serum SARS-CoV-2 antigen: A better predictor of COVID-19 severity

In this perspective, a new study published on the medRxiv* preprint server analyzed the clinical efficacy of two serum antigen tests to identify SARS CoV-2 infection and evaluate the kinetics of serum nucleocapsid (N) antigen in severe and non-severe patients for disease severity prediction.

24 Nov 2021

Paper-based innovations for COVID-19 diagnosis

A review discusses paper-based devices and platforms targeting SARS-CoV-2 for low-cost PoC diagnosis and serological antibody testing.

22 Nov 2021

Targeted proteomics for detection of SARS-CoV-2 proteins in clinical samples

A team of researchers from various institutions within the Netherlands examined the use of targeted MS-based proteomics for the detection of SARS-CoV-2 in research and clinical samples.

16 Nov 2021

Scientists develop a high-throughput, cell-free screening platform for anti-SARS-CoV-2 antibody discovery

Scientists from Northwestern University, USA, have recently developed a high-throughput, automated screening platform to rapidly identify anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies. The study is currently available on the bioRxiv* preprint server.

8 Nov 2021

Alzheimer’s Disease – A Global Response to a Global Challenge

Alzheimer’s Disease remains both a current issue and a future challenge. Levels of the disease in the European Union have been predicted to double from the current estimate of 7,853,705 to 14,298,671 by 2050

From Biophys Ltd. 8 Nov 2021

Development of SARS-CoV-2 detection platform using surface-enhanced Raman spectroscopy

Researchers have tried to develop an innovative platform for ultrasensitive and rapid detection of SARS-CoV-2 by exploiting a variation of Raman Spectroscopy.

4 Nov 2021

Antibody response of COVID-19 patients to SARS-CoV-2 and seasonal coronaviruses

Scientists conducted a cohort study and measured the prevalence and the levels of antibody responses to the nucleocapsid protein of SARS-CoV-2 and four seasonal human coronaviruses.

3 Nov 2021

BNT162b2 mRNA COVID-19 vaccine-induced antibodies wane over six month period

Researchers have been investigating the response of antibodies created against SARS-CoV-2 by the Pfizer-BioNTech six months after vaccination.

20 Oct 2021

Study detects the presence of SARS-CoV-2 in semen along with low sperm count

A new study reported findings of semen analysis from a prospective COVID-19 cohort study.

15 Oct 2021

Comparing lateral flow testing with RT-PCR to detect SARS-CoV-2

Lateral flow devices (LFDs) are point-of-care tests that require significantly more time to develop than RT-PCR assays but can be used locally with minimal to no training, some of which can provide results in as little as 30 minutes. However, there have been some worries about the sensitivity of such kits. As a result, researchers from Micropathology Ltd have been comparing the two methods.

12 Oct 2021

Anti-CD20 therapy patients can develop immune responses after SARS-CoV-2 vaccination

A new systematic review and meta-analysis focused on the humoral and cell-mediated immune responses after COVID-19 vaccination in patients undergoing anti-CD20 antibodies treatment.

5 Oct 2021

Study finds US pediatric COVID-19 cases are higher than expected

Researchers from the CDC have investigated differences in seroprevalence across pediatric age groups to estimate an infection to case ratio.

1 Oct 2021

Gyros Protein Technologies introduces Gyrolab AAV9 Titer Kit to support AAV-based cell and gene therapy production

Gyros Protein Technologies AB today announced the introduction of Gyrolab® AAV9 Titer Kit for rapid determination of titer in AAV9 vector-based cell and gene therapy manufacturing.

From Gyros Protein Technologies AB 30 Sep 2021

Study finds strong evidence of transplacental passage of IgG antibodies following COVID vaccination

In the current study, researchers investigate the transplacental transmission of antibodies in vaccinated pregnant women.

29 Sep 2021

A novel FACS-based approach for SARS-CoV-2 serology

A recent study discusses a simple, sensitive, and quantitative serological test based on FACS assay to evaluate antibodies against SARS-CoV-2.

20 Sep 2021

The Indian second wave: SARS-CoV-2 infection-induced immunity could be ineffective in protecting population

Researchers decided to investigate how effective immunity gained from previous SARS-CoV-2 infection protects a wider community from disease.

15 Sep 2021

Impact of prior SARS-CoV-2 infection and vaccine on antibody levels: Texas survey

A collaborative team, led by principal investigator Dr. Eric Boerwinkle, at The University of Texas Health Science Center at Houston, School of Public Health is conducting a survey designed to assess the frequency of antibody-positive individuals across Texas. The TEXAS Coronavirus Antibody REsponse Survey (CARES) aims to look for antibodies in the blood made in response to natural SARS-CoV-2 infection or vaccination.

14 Sep 2021